2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow LianBio LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations BBP-398, osimertinib - NSCLC | Phase 1 | Terminated | LianBio LLC | 4 | 2023-07-27 | 2024-06-25 |
| Phase I Study of the BBP-398 in Patients With Advance Solid Tumors BBP-398 - Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 | Terminated | LianBio LLC | 7 | 2022-10-18 | 2024-06-25 |
| Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects Mavacamten - Hypertrophic Cardiomyopathy | Phase 1 | Completed | LianBio LLC | 45 | 2021-10-31 | 2024-07-25 |
Carcinoma, Non-Small-Cell Lung (1) · Cardiomyopathy, Hypertrophic (1)
MYK-461 (1) · osimertinib (1)
China (3)
Li Zhang, Master (2) · Jing Zhang, Doctor (1) · Yongsheng Wang, Doctor (1)